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Abstract
Background: The immune-related evolution of influenza viruses is exceedingly complex and current vaccines against
influenza must be reformulated for each influenza season because of the high degree of antigenic drift among circulating
influenza strains. Delay in vaccine production is a serious problem in responding to a pandemic situation, such as that of the
current H1N1 strain. Immune escape is generally attributed to reduced antibody recognition of the viral hemagglutinin and
neuraminidase proteins whose rate of mutation is much greater than that of the internal non-structural proteins. As a
possible alternative, vaccines directed at T cell epitope domains of internal influenza proteins, that are less susceptible to
antigenic variation, have been investigated.
Methodology/Principal Findings: HLA transgenic mouse strains expressing HLA class I A*0201, A*2402, and B*0702, and
class II DRB1*1501, DRB1*0301 and DRB1*0401 were immunized with 196 influenza H1N1 peptides that contained residues
of highly conserved proteome sequences of the human H1N1, H3N2, H1N2, H5N1, and avian influenza A strains. Fifty-four
(54) peptides that elicited 63 HLA-restricted peptide-specific T cell epitope responses were identified by IFN-c ELISpot assay.
The 54 peptides were compared to the 2007–2009 human H1N1 sequences for selection of sequences in the design of a
new candidate H1N1 vaccine, specifically targeted to highly-conserved HLA-restricted T cell epitopes.
Conclusions/Significance: Seventeen (17) T cell epitopes in PB1, PB2, and M1 were selected as vaccine targets based on
sequence conservation over the past 30 years, high functional avidity, non-identity to human peptides, clustered
localization, and promiscuity to multiple HLA alleles. These candidate vaccine antigen sequences may be applicable to any
avian or human influenza A virus.
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Introduction
Influenza A viruses are major pathogens of avian origin with
global spread and rapid mutational change, some of which also
infect humans and other mammals. Of particular concern are the
several ways a human influenza pandemic could emerge. One is
through the occurrence of a novel and highly pathogenic zoonotic
strain capable of infecting humans, such as the H5N1 avian
pathogen. Another possibility is through mutation from a mild to a
more pathogenic human transmissible strain, such as mutation to
the current H1N1 strain. The most threatening is mutations giving
rise to a new highly transmissible-and-pathogenic human strain, as
occurred with the original 1918 Spanish influenza. In any event,
history teaches us that a vaccine to prevent a new influenza A
pandemic must be effective against all future forms of the virus.
Influenza A viruses are single stranded, negative-sense RNA
viruses belonging to the family Orthomyxoviridae. The genome is
composed of 8 RNA strands of about 13,500 bases, encoding at
least ten viral proteins. The viral envelope is a lipid bilayer,
consisting of the interior matrix protein 1 (M1) and three exterior
transmembrane proteins: hemagglutinin (HA), neuraminidase
(NA), and matrix protein 2 (M2). The viral core contains
viral ribonucleoprotein complex particles, consisting of viral
RNA, nucleoprotein (NP), and three polymerase proteins (PB1,
PB2, and PA). Mutation in the viral RNA genome occurs by
two mechanisms, known as antigenic drift and antigenic shift.
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Antigenic drift is the frequent occurrence of point mutations
resulting from defects in RNA replication mechanisms, while
antigenic shift is less frequent, involving re-assortment of the RNA
segments arising from exchanges between different strains in host
cells infected by multiple viruses.
Protection by current human influenza vaccines is achieved
by use of inactivated or attenuated forms of the corresponding
pathogen and appears to require the function of neutralizing
antibodies against the external HA and NA glycoproteins.
However, these glycoproteins mutate rapidly through antigenic
drift and current vaccines become ineffective as mutational
differences accumulate in the circulating strains. In order to
overcome the antigenic variability of influenza external glyco-
proteins, new vaccine strategies are increasingly directed at
conserved regions of the viral proteins for production of T
cell epitope-based vaccines. The goal is to identify conserved
sequences that function as epitopes recognized by human
leukocyte antigen (HLA) molecules for presentation to CD8+
and CD4+ T cells that provide immunity against all influenza A
virus subtypes and obviate the need for yearly vaccine update.
Several animal model studies taking this approach have reported
T cell responses that reduce morbidity and promote recovery in
mouse models of influenza challenge [1–4]. Both CD8+ and
CD4+ T cell responses are required; CD8+ T cells to kill infected
cells [5,6] and CD4+ T cells for the development of an effective
immune response and immune memory [7–9]. A complication of
cellular immunity is that T cell responses are dependent upon
antigen presentation by highly polymorphic HLA molecules that
vary greatly among human populations. However, the limited
population coverage of some HLA alleles may be alleviated by
focusing on T cell epitopes recognized by HLA supertypes that
bind largely overlapping peptide repertoires on the basis of the
specificity for the main anchor positions of the presented peptides
[10,11].
We previously reported a detailed study of evolutionarily
conserved sequences of all human and avian influenza A viruses
that were recorded over the past 30 years (36,343 sequences) [12].
Fifty-four (54) sequences, ranging from 9 to 58 amino acids (aa) of
the PB2, PB1, PA, NP, and M1 sequences were conserved in at
least 80%, and in most cases 95–100% of all recorded human
H1N1, H3N2, H1N2, and H5N1, and avian subtypes. These
sequences have remained evolutionarily stable for all recorded
human and avian influenza A viruses during the past decades, and
are thus prime candidates for the development of T cell epitope-
based vaccines against multiple influenza strains. However, the
function of these conserved sequences as HLA-restricted T cell
epitopes and the incidence of variant sequences in association with
the conserved sequences were not known. Herein, we have focused
on the identification and characterization of peptides of influenza
virus A/New York/348/2003 (H1N1) that contain conserved
sequences and elicit HLA-restricted T cell responses. HLA
transgenic mice (HLA-A2, -A24, -B7, -DR2, -DR3, and -DR4)
were immunized with the selected peptides. The peptides that
elicited T cell activation by IFN-c ELISpot assay and thus
contained T cell epitopes were selected and analyzed for properties
relevant to vaccine development, including evolutionary conser-
vation and diversity, and correspondence to the 2007–2009
human H1N1 sequences.
Materials and Methods
Ethics Statement
Mice were maintained in a pathogen-free facility at the Johns
Hopkins University according to IACUC guidelines.
Influenza Peptides
Peptide arrays of PB2 (BEI Cat.: NR-2616), PB1 (NR-2617), PA
(NR-2618), NP (NR-2611), and M1 (NR-2613) of influenza virus
A/New York/348/2003 (H1N1) were obtained through the NIH
Biodefense and Emerging Infections Research Resources Repos-
itory, NIAID, NIH (BEI). A total of 196 peptides (all 17 aa long
except PB2268–283 and 393–408) were selected to fully cover all
highly conserved sequences under study. Where these sequences
spanned two or more 17 aa peptides, the consecutive peptides
were overlapped by 11 aa (Figure S1). Two immunization peptide
pools for immunization were formed: one composed of 84 PB2
and 13 M1 peptides (Table S1), and the second composed of 48
PB1, 23 PA, and 28 NP peptides (Table S2). Each of the 196
peptides was dissolved in 100% DMSO and constituted to 20%
with sterile filtered water. The final concentration of each peptide
was 2 mg/ml. The dissolved peptides were stored at 220uC.
HLA Transgenic Mice
Six different strains of HLA transgenic mice were used to cover
HLA alleles of class I and class II supertypes. These six alleles were
selected based on their prevalence in the Caucasian population
and the availability of HLA transgenic mouse strains in our
laboratory. The HLA class I supertypes studied were HLA-A2
(A*0201) mice expressing a chimeric heavy chain with murine a3
domain and human b2m. Both H-2Db and murine b2m genes
were disrupted by homologous recombination [13], HLA-A24
(A*2402) mice express a chimeric heavy chain and human b2m;
the H-2Kb, H-2Db, and murine b2m genes were disrupted by
homologous recombination (Lemonnier et al., unpublished), HLA-
B7 (B*0702) mice express a chimeric heavy chain with the HLA-
B*0702 a1 and a2 domains and the H-2Kd murine a3 domain
[14]. The H-2Kb and H-2Db genes in HLA-B7 mice were
inactivated by homologous recombination. The HLA-A2 and -B7
transgenic mice were kind gifts from Steve Pascolo (Institut
Pasteur, France) and Pierre-Simon Rohrlich (Institut Pasteur,
France), respectively.
The HLA class II supertypes studied herein were DR2
(DRB1*1501), DR3 (DRB1*0301), and DR4 (DRB1*0401) where
HLA-DR2, -DR3, and -DR4 transgenic mice were kind gifts from
Lars Fugger (Weatherall Institute of Molecular Medicine, Oxford,
UK) and Arthur Vanderbark (Oregon Health and Science
University, Portland), Chella S. David (Mayo Clinic, Rochester),
and Grete Sønderstrup (Stanford University School of Medicine),
respectively. The peptide-binding domain of HLA-DR2 transgenic
mice is encoded by human sequences, while the membrane
proximal portion containing the CD4-binding domain is encoded
by mouse sequences (DRA1*0101: I-Ea and DRB1*1501: I-Eb)
[15]. HLA-DR3 transgenic mice express HLA-DRA*0101 and
-DRB1*0301 [16]. HLA-DR4 transgenic mice express HLA-
DRA*0101, -DRB1*0401, and human CD4 [17]. The derivation
and validation of the above transgenic mice has been described in
the cited publications.
Immunization
Mice were immunized with the selected 196 peptides in 2 pools
by use of a protocol which had been validated for T cell studies
[18] and adapted for these transgenic mice studies. Peptides were
pooled in matrixes as described [19] and injected in groups of 9
mice of each transgenic strain: two for matrix array screening, two
for identifying individual peptides, four for characterizing
apparent functional avidity of T cells to positive peptides at three
titration points: 10, 1, and 0.1 mg/ml peptide concentrations, and
one as a control (adjuvant alone). Mice were injected subcutane-
ously at the base of tail with 100 ml of the immunization peptide
A(H1N1)T Cell Epitopes
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pool in TiterMaxH Gold adjuvant (TiterMax, Norcross, GA) (1:1).
The amount of each peptide injected was 1 mg/mouse. After two
weeks, spleens were harvested for IFN-c ELISpot assay.
IFN-c ELISpot Assay
Harvested spleens from immunized transgenic mice were
selectively depleted of CD8+ or CD4+ T cells by use of anti-
CD8 or anti-CD4 antibody-coated immunomagnetic beads with
LD columns (Miltenyi Biotec, Auburn, CA) according to the
manufacturer’s protocol. The resulting CD8+ or CD4+ depleted
splenocytes were tested individually by IFN-c ELISpot assays
against the 196 influenza peptides arranged in two 10610 matrix
arrays, resulting in 40 peptide pools, where each peptide was
present in two different pools, as described [19]. Peptides identified
as immunogenic in the matrix array screen were retested
individually in a confirmatory assay and a peptide titration assay.
Thus, each ELISpot positive response was detected three times: by
matrix array screening, individually by confirmatory assay, and by
peptide titration.
The ELISpot assays were performed using mouse IFN-c
ELISpot sets from BD Biosciences (San Jose, CA) according to
the manufacturer’s protocol. Briefly, the ELISpot plates were
coated with anti-IFN-c at 5 mg/ml and incubated at 4uC
overnight. The plates were blocked with RPMI 1640 containing
10% heat-inactivated fetal calf serum, 2 mM L-glutamine,
100 mg of streptomycin/ml, and 100 U of penicillin for 2 h at
room temperature, and either CD8+- or CD4+-depleted spleno-
cytes (0.521.06106 cells/well) were then added for assays of
class II and I T cell epitopes, respectively. The cells were cultured
at 37uC in 5% CO2 in the presence of peptide pools (final
concentration of each peptide was 10 mg/ml) or individual
peptides at final concentrations of 10 mg/ml, 1 mg/ml, and
0.1 mg/ml. Wells with medium alone served as background;
Concanavalin A (2.5 mg/ml; Sigma-Alrich, St. Louis, MO) was
used as a polyclonal stimulator; and known HLA-restricted
peptides from Dengue serotype 3 were included in each assay as
positive controls. After 16 h of culture, the plates were washed
and incubated with biotinylated anti-IFN-c for 2 h at room
temperature, followed by HRP-conjugated streptavidin for 1 h
at room temperature. Reactions were developed with AEC
substrate (Calbiochem-Novabiochem, San Diego, CA). Final
enumeration of IFN-c spot-forming cells (SFC) was performed
using the Immunospot Series 3B Analyzer ELISPOT reader
(Cellular Technologies, Shaker Heights, OH) with aid of the
Immunospot software version 3.0 (Cellular Technologies),
indicating the number of SFC/106 cells. The results were
considered positive if the number of SFC subtracted by those in
the background (culture with medium alone) was above 10 and
the number of SFC was higher than the background plus two
standard deviations. The results shown are SFC minus back-
ground, which was consistently found to be less than 15 spots/106
cells throughout the experiments.
Experimentally Identified Human T Cell Epitopes in the
Highly Conserved Sequences of Influenza A Viruses
Published influenza T cell epitopes within the highly conserved
sequences were identified by use of the Immune Epitope Database
and Analysis Resource (IEDB, http://www.immuneepitope.org/)
[20]. The published epitope sequences were derived from various
T cell assays that included T cell proliferation, IFN-c ELISpot,
HLA tetramer staining, and 51Cr release assays. Only epitope data
from unique sequences and containing HLA restriction informa-
tion were included.
Determination of Human Self-Peptide in Influenza
Peptides
The 196 influenza 17 aa peptides were compared using the
blastp program against the non-redundant protein sequences
database restricted to human (taxid:9606) at NCBI (http://ww.
ncbi.nlm.nih.gov/BLAST/) to detect the presence of fragments
identical to human peptides. As the default search parameters
were not suitable to probe for short peptide sequences of length 30
or less, the following parameters were used: word size of 2,
expectation value of 30,000, matrix was PAM30, low complexity
filter was disabled, and composition-based statistics was set to ‘no
adjustment’. We disregarded search results containing predicted
sequences and human peptides with fewer than six contiguous
identical residues as the probability of matching five or less
residues is high and non-significant.
Conservation of Influenza A (H1N1) T Cell Epitopes
The dataset and methodology for identification of highly
conserved influenza protein sequences among pathogenic influ-
enza strains for the past 30 years had been described by Heiny
et al. [12]. Briefly as reported, 3763 NP, 3781 M1, 3111 PA, 3175
PB1, and 3144 PB2 sequences were extracted from the NCBI
GenBank and GenPept databases (as of September 2006) and
multiple sequence alignments of the individual proteins were
performed. The Antigenic Variability Analyzer (AVANA) tool
[21] was used to identify the most frequent 17 aa sequence present
in at least 80% of all the recorded viruses.
The 2007–2009 human H1N1 sequences were compared with
the T cell epitopes of A/New York/348/2003 (H1N1), by aligning
the protein sequence records of human H1N1 M1, PB1, and PB2
retrieved from the NCBI Influenza Virus Sequence Database
(http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html, as of
Jun 17, 2009) and application of the AVANA tool to identify
the most frequent sequence and its variants for each year.
Results
HLA-Restricted Epitopes of Highly Conserved Human and
Avian Influenza A Virus Sequences
The previously described 54 highly conserved influenza A
sequences of 9 or more contiguous aa of the recorded human and
avian influenza strains were represented by a total of 956 aa of the
M1, NP, PA, PB1, and PB2 proteins [12]. The majority of the
conserved sequences, 650 aa, were in the PB1 and PB2 proteins;
there were no conserved sequence in NA, M2, NS1, and NS2. A
total of 196 peptides (BEI) of the A/New York/348/2003 (H1N1)
M1, NP, PA, PB1, and PB2 proteins were selected based on the
presence of the conserved sequences. The immunogenicity of these
196 conserved influenza peptides was studied by immunizing
HLA-A2, -A24, -B7, -DR2, -DR3, and -DR4 transgenic mice.
Organization of the 54 conserved sequences in the BEI 17 aa
peptides depended on their length and position. Conserved
sequences that spanned adjacent 17 aa peptides were repeated
up to a maximum of 11 aa because of overlapping peptide
synthesis (Tables S1 & S2, Figure S1). Peptides with conserved
sequences of less than 17 aa contained mixtures of conserved and
non-conserved aa. Thirty-two (32) short conserved sequences (9 to
16 aa) were present in various lengths with adjacent non-conserved
aa. Conserved sequences of greater length (22 sequences of 17 to
57 aa) were present as complete (65 of the 196 peptides) or partial
sequences in the overlapping peptides. The longest conserved
sequence was PB1518–575 which was included as part of a cluster of
completely conserved aa of 7 overlapping peptides.
A(H1N1)T Cell Epitopes
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Table 1. HLA-A24, -B7, -DR2, -DR3, and -DR4 restriction of 54 peptides of influenza proteins M1, NP, PA, PB1, and PB2 that contain
conserved sequences of 9 or more amino acids.
Protein ELISpot positive 17 aa peptide* A24# B7 DR2 DR3 DR4
M1 169 TNPLIRHENRMVLASTT 185 - - 5665 (0.1) 12064 (0.1) -
175 HENRMVLASTTAKAMEQ 191 - - - - 16561 (0.1)
181 LASTTAKAMEQMAGSSE 197 - - - - 115621 (1)
NP 7 KRSYEQMETDGERQNAT 23 - - - - 52629 (0.1)
31 RMIGGIGRFYIQMCTEL 47 4565 (0.1) - - - -
37 GRFYIQMCTELKLNDYE 53 - - - 6667 (1) -
73 ERRNKYLEEHPSAGKDP 89 - - - - 12161 (0.1)
103 KWVRELVLYDKEEIRRI 119 - - - 614621 (0.1) -
109 VLYDKEEIRRIWRQANN 125 - - - 501642 (0.1) -
133 LTHIMIWHSNLNDTTYQ 149 - - 238659 (0.1) - -
402 SAGQISTQPTFSVQRNL 418 - - 20763 (0.1) - -
408 TQPTFSVQRNLPFDKTT 424 - - 110614 (1) 4162 (10) -
PA 42 LEVCFMYSDFHFINEQG 58 - - 64611 (1) - -
126 EVHIYYLEKANKIKSEK 142 - - - - 37611 (0.1)
132 LEKANKIKSEKTHIHIF 148 - - - - 41610 (0.1)
558 SRPMFLYVRTNGTSKIK 574 - - - - 114624 (0.1)
PB1 31 SHGTGTGYTMDTVNRTH 47 - - - - 10661 (0.1)
37 GYTMDTVNRTHQYSERG 53 - - - - 125611 (0.1)
120 DKLTQGRQTYDWTLNRN 136 - - - 14266 (0.1) -
126 RQTYDWTLNRNQPAATA 142 - - - 7860 (0.1) -
328 NQPEWFRNILSIAPIMF 344 - 6068 (10) - - -
340 APIMFSNKMARLGKGYM 356 - - - 17560 (0.1) -
352 GKGYMFESKSMKLRTQI 368 - - 5262 (1) - -
358 ESKSMKLRTQIPAEMLA 374 - - 84620 (0.1) - -
465 RFYRTCKLLGINMSKKK 481 - - 231673 (1) - -
471 KLLGINMSKKKSYINRT 487 - - - 116+10 (0.1) -
489 TFEFTSFFYRYGFVANF 505 21369 (0.1) - - - -
495 FFYRYGFVANFSMELPS 511 210625 (0.1) - - - -
507 MELPSFGVSGVNESADM 523 - - - - 274615 (0.1)
519 ESADMSIGVTVIKNNMI 535 - - 75610 (0.1) - -
525 IGVTVIKNNMINNDLGP 541 - - 159653 (0.1) - -
537 NDLGPATAQMALQLFIK 553 9262 (1) - - - -
548 LQLFIKDYRYTYRCHRG 564 - - 6162 (1) 230+23 (0.1) 97630 (0.1)
554 DYRYTYRCHRGDTQIQT 570 - - 109613 (1) 166622 (0.1) 7662 (0.1)
560 RCHRGDTQIQTRRSFEI 576 - - 194647 (0.1) - -
650 GPAKNMEYDAVATTHSW 666 - - - 142645 (0.1) 4169 (0.1)
656 EYDAVATTHSWVPKRNR 672 - - - - 5962 (0.1)
680 RGILEDEQMYQRCCNLF 696 7864 (0.1) - - 181610 (0.1) -
PB2 42 NPSLRMKWMMAMKYPIT 58 - - - - 16663 (0.1)
48 KWMMAMKYPITADKRIT 64 - - - - 161618 (0.1)
54 KYPITADKRITEMIPER 70 - - - 49964 (0.1) -
126 KHGTFGPVHFRNQVKIR 142 - - - - 316620 (0.1)
132 PVHFRNQVKIRRRVDIN 148 - - - - 311637 (0.1)
256 DQSLIIAARNIVRRAAV 272 - - - 169612 (0.1) -
369 RATAILRKATRRLIQLI 385 - - - - 5462 (0.1)
434 LLRHFQKDAKVLFLNWG 450 - - - 444614 (0.1) -
458 MGMIGILPDMTPSTEMS 474 - - - - 23865 (0.1)
464 LPDMTPSTEMSMRGVRV 480 - - - 324628 (0.1) -
500 RFLRVRDQRGNVLLSPE 516 - 18463 (0.1) - - -
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Immunization of the HLA transgenic mice with the 196 H1N1
peptides was carried out with 2 pools of about 100 peptides each,
with groups of 9 mice of each transgenic strain. Interferon-c (IFN-
c) ELISpot assays for HLA-restricted class I and class II responses
were performed with splenocytes of the immunized mice that were
depleted of CD4+ and CD8+ T cells, respectively, to identify the
responding T cell subset. The initial assays contained matrix
arrays of peptide pools followed by validation assays with
individual peptides [19]. Of the 196 peptides, 54 contained T
cell epitopes that elicited 63 ELISpot responses (8 A24, 2 B7, 16
DR2, 17 DR3, and 20 DR4) (Table 1). None of the 196 peptides
tested induced T cell responses in mice expressing the HLA-A2
allele. Forty-seven (47) of the 54 epitopes were restricted by one
HLA allele; eight by class I HLA-A24 and -B7, and 39 by class II
HLA-DR2, -DR3, and -DR4. The remaining 7 peptides contained
epitopes that were presented by at least two HLA alleles of distinct
supertypes i.e. they contained multiple or promiscuous T cell
epitopes. Epitopes of PB1680–696 and PB2548–564 were presented by
both HLA class I and II alleles. Sixteen (16) pairs of consec-
utive peptides were restricted by the same HLA allele, possibly
because there were identical epitopes in the overlapping 11 aa
sequence shared by the 2 adjacent peptides. Clusters of 2 or more
T cell epitopes with at least 16 conserved aa were M1175–197,
PB1120–142, 340–374, 489–576, and PB242–64, 126–146 (Table 1, Figure 1).
The apparent functional avidity of T cells to each of the 54
peptides was titrated at three peptide concentrations of 10, 1 and
0.1 mg/ml in IFN-c ELISpot assays. Of the 63 positive ELISpot
responses, including the responses of peptides restricted by
multiple HLA alleles, 52 activated IFN-c secretion at each of
the three concentrations used in the ELISpot assay, 9 elicited at
concentrations of 10 and 1 mg/ml, and 2 peptides (NP408–424 and
PB1328–344) elicited solely at the highest peptide concentration
(Table 1).
Presence of Reported Human T Cell Epitopes in the
Conserved Sequences of Influenza A
The conserved peptides of this study were compared with
reported T cell epitope sequences of humans infected with
influenza A viruses extracted from the IEDB [20]. Twenty-one
(21) of about 800 reported human T cell epitopes of PB2, PB1, PA,
NP, and M1 were found to contain sequences of 9 or more
conserved amino acids of all recorded 1977–2006 influenza A
viruses (Table 2). These HLA-restricted T cell epitopes were
mainly from H1N1, H3N2, and H5N1 infections and included
sequences restricted by a broad range of HLA class I and II alleles,
including many alleles not covered by the transgenic mice of this
study. For example, the same T cell epitope ‘‘RMVLASTTAK’’
in M1178–187 was reported to be restricted by HLA-A3 and -A11
[22,23]. Clusters of overlapping epitopes were also observed
within the conserved sequences, for example, M1123–137 had three
overlapping epitopes (123 ALASCMGLIY 132 was restricted by A1;
125 ASCMGLIY 132 by B35; and 129 GLIYNRMGA 137 by A2)
[22,24]. Thus, the highly conserved sequences contained common
epitopes shared by pathogenic influenza strains and could be
restricted by a broad range of HLA alleles.
Analysis of the Presence of Human Peptide Sequences in
Influenza Peptides
Each of the 196 influenza 17 aa peptides used in this study was
compared with human proteome sequences to investigate the
Protein ELISpot positive 17 aa peptide* A24# B7 DR2 DR3 DR4
524 TEKLTITYSSSMMWEIN 540 - - 151667 (0.1) - -
536 MWEINGPESVLINTYQW 552 289616 (0.1) - - - -
542 PESVLINTYQWIIRNWE 558 22665 (0.1) - - - -
548 NTYQWIIRNWETVKIQW 564 322644 (0.1) - 9669 (0.1) - -
630 RMQFSSLTVNVRGSGMR 646 - - 104616 (0.1) - -
ELISpot responses 8 2 16 17 20
*Conserved aa are boldface. Consecutive peptides overlapping by 11 aa are aligned.
#Numbers are representative average IFN-c spots forming cells per million splenocytes of individual transgenic mice that were positive at 10 mg/ml of peptide
concentration. Number (10, 1 or 0.1) in parenthesis represents the lowest concentration of peptide (mg/ml) giving positive ELISpot response in peptide titration.
-represents no positive IFN-c ELISpot response.
doi:10.1371/journal.pone.0008754.t001
Table 1. Cont.
Figure 1. Localization of HLA-restricted T cell epitopes of
conserved sequences of influenza polymerases, NP, and M1
proteins. Numbers represent aa positions. Highly conserved aa are
shown as grey boxes. T cell epitopes were restricted by HLA-DR4 (black
boxes), -DR3 (blue boxes), -DR2 (brown boxes), -A24 (green boxes), and
-B7 (orange boxes).
doi:10.1371/journal.pone.0008754.g001
A(H1N1)T Cell Epitopes
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possibility of identity to human self-antigens that could trigger an
autoimmune response to immunization. Specifically, we screened
for exactly identical sequences of at least 8 continuous aa, the
minimum binding peptide length for MHC class I [25]. Many of
the conserved sequences of the influenza peptides contained
sequences of 6 aa found in human proteins such as voltage-gated
sodium channel, dystrophin etc. The longest influenza A sequence
with an identical human counterpart was 7 aa of PA131–137 but
none contained sequences of 8 or more aa identical to the human
proteome (Table 3).
Variants of the Conserved T Cell Epitope Sequences
The 54 HLA-restricted T cell epitopes of A/New York/348/
2003 (H1N1) strain were analyzed by the Antigenic Variability
Analyzer (AVANA) tool [21] for identification of (a) the consensus
sequence (most frequent sequence) in the context of influenza A
conserved sequences over the past 30 years, and (b) variants and
percentage conservation of 2007–2009 human H1N1 strains as
compared to the 2003 H1N1 strain. Based on their conservation
and diversity, the 54 T cell epitopes formed three groups:
1) Seventeen (17) T cell epitope sequences of the 2003 strain (11
PB1, 4 PB2, and 2 M1) were conserved in at least 88% of all
recorded human and avian influenza strains (Table 4). In
particular, PB1489–505 was 100% conserved in all H1N1
viruses. Several variant sequences within this group were
recorded, but these were mostly single conservative amino
acid substitutions representing a small fraction (less than 5%)
of all the recorded 1977–2006 virus sequences. The major
change in 2009 was the apparent complete replacement of 2
previous consensus sequences by variant sequences, each with
1 mutated aa (PB2132–148, 630–646).
2) A group of 9 PB1 and PB2 T cell epitopes of the A/New
York/348/2003 H1N1 strain was variants of the 1977–2006
total recorded influenza A virus population at a single
mutated aa position (Table 5). These variant A/New York/
348/2003 strain sequences represented less than 15% of the
consensus sequences of the entire 1977–2006 avian and
human virus population. One of these, PB1507–523, became
the H1N1 consensus sequence of 2007–2009. For the others,
a single aa modification to the BEI peptide would result
in 96–100% representation in the 2009 human H1N1
population.
3) The remaining 28 peptides were each represented in the
dataset by 2 to 7 variant sequences with multiple mutations
(Table S3). The A/New York/348/2003 sequences were the
predominant form in only 13 of the 28 peptides and at
reduced representations of 6 to 72% of the recorded viruses.
As the variant forms contained a mixture of conserved
sequences and variable amino acids, it is not possible to
predict the immunogenicity of the variant sequences
represented in nature and their use as vaccine sequences.
Table 2. Presence of reported human influenza A T cell epitopes in 21 highly conserved sequences of A/New York/348/2003
(H1N1).
Highly conserved 17 aa peptide*
HLA allele
this work# Published HLA alleles Influenza strain
M1 1 MSLLTEVETYVLSIVPS 17 - A2 A/Puerto Rico/8/34 (H1N1)
M1 121 AGALASCMGLIYNRMGA 137 - A1, A2, B35, DRB1*0404 A/Vietnam/1203/2004 (H5N1), Influenza A (H3N2)
M1 169 TNPLIRHENRMVLASTT 185 DR2, DR3 B39, DR2, DRB1*0103, DRB1*1101,
DRB1*0701, DRB5*0101
A/Vietnam/1203/2004 (H5N1), Influenza A
M1 175 HENRMVLASTTAKAMEQ 191 DR4 A3, A11, DRB1*0701 A/Puerto Rico/8/34 (H1N1), A/Vietnam/1203/2004
(H5N1)
NP 61 LTIERMVLSAFDERRNK 77 - A3 Influenza A
NP 67 VLSAFDERRNKYLEEHP 83 - DRB1*0101 A/Vietnam/1203/2004 (H5N1)
NP 73 ERRNKYLEEHPSAGKDP 89 DR4 DR1, DRB1*0101 A/NT/60/68 (H3N2), A/Vietnam/1203/2004 (H5N1)
NP 91 KTGGPIYKRVDGKWVRE 107 DR3 A68 A/Texas/1/77 (H3N2)
NP 109 VLYDKEEIRRIWRQANN 125 DR3 DRB1*1101 A/Vietnam/1203/2004 (H5N1)
NP 402 SAGQISTQPTFSVQRNL 418 DR2 DRB1*0101, DRB1*0404 A/Vietnam/1203/2004 (H5N1)
PA 42 LEVCFMYSDFHFINEQG 58 DR2 A2 A/Puerto Rico/8/34 (H1N1)
PB1 1 MDVNPTLLFLKVPAQNA 17 - A2 Influenza A
PB1 37 GYTMDTVNRTHQYSERG 53 DR4 A26 Influenza A
PB1 346 NKMARLGKGYMFESKSM 362 - B62, B27 Influenza A
PB1 352 GKGYMFESKSMKLRTQI 368 DR2 B44 Influenza A
PB1 489 TFEFTSFFYRYGFVANF 505 A24 A1, B44 Influenza A
PB1 501 FVANFSMELPSFGVSGV 517 - A2 Influenza A
PB1 537 NDLGPATAQMALQLFIK 553 A24 B7 Influenza A
PB1 560 RCHRGDTQIQTRRSFEI 576 DR2 B62 Influenza A
PB1 566 TQIQTRRSFEIKKLWDQ 582 - B27 Influenza A (H3N2)
PB2 48 KWMMAMKYPITADKRIT 64 DR4 A2 A/Puerto Rico/8/34 (H1N1)
*Conserved aa are boldface. Published HLA epitopes were extracted from the IEDB. HLA class I epitopes are italicized. HLA class II epitopes longer than 17 aa are
represented only by the corresponding residues in the 17 aa peptides of A/New York/348/2003 (H1N1).
#- represents no positive IFN-c ELISpot response.
doi:10.1371/journal.pone.0008754.t002
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These data demonstrated that when T cell epitopes contain
mixtures of conserved and non-conserved aa, the occurrences
of mutated sequences in a subsequent influenza A strain are
greatly enhanced.
Discussion
An enigma of the immunobiology of influenza A is that vaccines
fail to provide long term protection against infection and natural
infection does not prevent reinfection. The rapid mutation of the
viral proteins, particularly the external HA and NA proteins that
are targets for neutralizing antibodies, is credited with a significant
role in this loss of immunity. Defective adaptive immunity is also
observed with several RNA viruses (including HIV-1 and dengue
viruses) with high rates of mutation that result in multiple genetic
variants bearing mutated T cell epitope sequences. This has
resulted in widespread attention to the use of conserved T cell
epitopes of non-structural viral internal proteins [26–29]. Howev-
er, the occurrence of reinfection, despite the human T cell
response to conserved sequences after natural infection, suggests
the function of a viral mechanism that negatively effects in the host
immune response to influenza infection. One possibility is the dual
immunosuppressor roles of the influenza A NS1 protein that
inhibit innate immunity by preventing type I IFN release, as well
as adaptive immunity by attenuating human dendritic cell
maturation and the capacity of dendritic cells to induce T cell
responses [30]. There is also the concepts of immunological
‘‘original sin’’ and altered epitope ligands where mutations in or
adjacent to T cell epitopes preserve binding to MHC molecules
but present an altered surface to the original T cell antigen
receptor, resulting in an impaired or modified T cell response,
including T cell immunosuppression [31–37]. Thus, variant
viruses bearing mutated T cell epitopes escape memory T cells
recognizing the initial epitopes, leading to impaired clearance of
variant viruses reinfecting the same individuals.
In this study, HLA transgenic mice, HLA-A2, -A24, -B7, -DR2,
-DR3, and DR4, were immunized with 196 overlapping H1N1
peptides of the A/New York/348/2003 strain that contained the
highly conserved sequences of the M1, NP, PB1, PB2, and PA
proteins of all recorded human and avian influenza A viruses of
the past 30 years [12]. Fifty-four (54) of these peptides (22 PB1, 16
PB2, 9 NP, 4 PA, and 3 M1) elicited 63 HLA-restricted T cell
responses by IFN-c ELISpot assay, where 7 peptides were
restricted by multiple alleles. It should be recognised that the
HLA-restricted T cell activation elicited by these peptides in the
transgenic mice identified peptides that contain T cell epitopes,
but not the specific identity of the T cell epitopes. While current
convention refers to antigenic sequences recognized by T cells in
association with an HLA molecule as ‘‘epitopes,’’ this term was
introduced by Niels K. Jerne in 1960 in relation to defined
structures recognized by antibodies. In contrast, he used the term
‘‘cryptotopes’’ to define the processed peptides that are recognized
by T cells in association with an HLA molecule. There are very
few sequences called T cell epitopes for which the actual structures
of the epitopes are known. Moreover, as is shown in the text, 7 of
the peptides elicit responses in 2 or 3 HLA transgenic mice,
indicative of multiple or promiscuous epitopes in each peptide.
Many of the epitope peptide sequences reported herein also
contain sequences reported by others as T cell epitopes of
individuals infected by H1N1, H3N2, and H5N1 viral strains
Table 3. Determination of human self-peptides in representative influenza 17aa peptides.
Viral peptide* Human peptide Human protein name GenPept ID
M1 169 TNPLIRHENRMVLASTT 185 26 MVLAST 31 Ring finger protein 220 NP_060620
M1 175 HENRMVLASTTAKAMEQ 191 140 TAKAME 145 Mediator of cell motility 1 NP_057039
M1 181 LASTTAKAMEQMAGSSE 197 1387 EQMAGS 1392 MYST histone acetyltransferase 3 NP_001092882
NP 7 KRSYEQMETDGERQNAT 23 582 KRSYEQ 587 Metastasis associated protein NP_004680
NP 103 KWVRELVLYDKEEIRRI 119 121 EEIRRI 126 Annexin IV NP_001144
NP 402 SAGQISTQPTFSVQRNL 418 80 PTFSVQ 85 Mucin 6, gastric NP_005952
NP 408 TQPTFSVQRNLPFDKTT 424 1805 QPTFSV 1810 Chromodomain helicase DNA binding protein 9 NP_079410
PA 126 EVHIYYLEKANKIKSEK 142+ 1266 YLEKANK 1272 Dystrophin Dp427c isoform NP_000100
1274 YLEKANK 1280 Dystrophin Dp427m isoform NP_003997
1151 YLEKANK 1157 Dystrophin Dp427l isoform NP_003998
1270 YLEKANK 1276 Dystrophin Dp427pl isoform NP_004000
PB1 31 SHGTGTGYTMDTVNRTH 47 3151 GYTMDT 3156 Polydom NP_699197
PB1 31 SHGTGTGYTMDTVNRTH 47 2141 TGYTMD 2146 Multiple EGF-like-domains 8 NP_001401
PB1 471 KLLGINMSKKKSYINRT 487 609 MSKKKS 614 Suppressor variegation 4–20 homolog 1 isoform 1 NP_060105
PB1 489 TFEFTSFFYRYGFVANF 505 561 SFFYRY 566 Phosphatidylinositol glycan anchor biosynthesis NP_036459
PB1 537 NDLGPATAQMALQLFIK 553 919 PATAQM 924 Rho GTPase-activating protein NP_055530
PB1 548 LQLFIKDYRYTYRCHRG 564 231 DYRYTY 236 Syntaxin binding protein 5 isoform a NP_640337
PB2 256 DQSLIIAARNIVRRAAV 272 725 ARNIVR 730 Akt substrate AS250 NP_065076
PB2 256 DQSLIIAARNIVRRAAV 272 1301 IAARNI 1306 ATP-binding cassette, sub-family A, member 6 NP_525023
PB2 458 MGMIGILPDMTPSTEMS 474 1964 DMTPST 1969 Voltage-gated sodium channel Type II, isoform 1 NP_066287
PB2 458 MGMIGILPDMTPSTEMS 474 1964 DMTPST 1969 Voltage-gated sodium channel Type II, isoform 2 NP_001035233
*Conserved aa are boldface.
+PA131–137 shared 7 aa identity with human Dystrophin Dp427 isoform proteins.
doi:10.1371/journal.pone.0008754.t003
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and restricted by a broad range of HLA class I and II alleles.
Thus, it is reasonable to expect that the conserved peptides
identified here can elicit human T cell epitope responses in the
context of several HLA alleles and HLA-supertypes [38] and
that the memory T cells can cross-react with epitopes from
H1N1, H3N2, and H5N1 [27,39,40]. The class I alleles
described herein HLA-A*0201, -A*2402, and -B*0702 belong
to the distinct supertypes A2, A24, and B7, respectively [10,11].
HLA class II supertypes are not as well documented but the 3
alleles of the transgenic mice of this study are assigned to
supertypes DR1, DR3, and DR4 [41] based on similar protein
and three-dimensional structures. Thus, fewer HLA alleles
within the supertypes could be selected to protect a broad
population in contrast to selection of individual alleles.
Analysis of the conservation and mutational variants of these
H1N1 HLA-restricted epitopes was revealing of the marked effect
that single aa mutations may have on the representation of
T cell epitopes in evolving virus populations. Over the 3 years
interval (2007 to 2009) between the database records analyzed by
Heiny et al. (2006) to the current 2009 H1N1 sequence analysis,
only 8 of the 54 highly conserved T cell epitope sequences were
without mutational change. These 8 peptides (M1175–191, 181–197,
PB131–47, 120–136, 126–142, 489–505, 495–511, and 548–564) were
representative of almost complete conservation, 95–100%, during
the previous recorded history of human H1N1 virus sequences. All
others of the identified HLA-restricted T cell epitopes contained at
least 1 aa substitution, primarily but not exclusively, of the non-
conserved aa of the H1N1 peptides. Our data suggest that the
most favorable sequences for a T cell epitope-based vaccine are
the 17 H1N1 T cell epitopes of the PB1, PB2, and M1 proteins
(Table 4). We are presently investigating the protective effect of
these sequences against live influenza challenge. These 17 T cell
epitopes were highly conserved over the 33 years (1977–2009) of
the examined database records, representing 88 to 100% of all
Table 4. Representation of 17 H1N1 T cell epitope sequences among all influenza A 1977–2006 strains and H1N1 strains 2007–
2009 that corresponded to the most frequent sequences with at least 88% conservation.
Protein
A/New York/348/2003 H1N1
ELISpot positive peptide1
1977--2006
Influenza A*
2007 human
H1N10
2008 human
H1N1 “
2009 human
H1N1+
PB1 31 SHGTGTGYTMDTVNRTH 47 99 100 100 100
120 DKLTQGRQTYDWTLNRN 136 97 100 100 100
126 RQTYDWTLNRNQPAATA 142 99 100 100 100
340 APIMFSNKMARLGKGYM 356 96 98 100 92
-------------R--- 2 2 - 8
489 TFEFTSFFYRYGFVANF 505 100 100 100 100
495 FFYRYGFVANFSMELPS 511 99 100 100 100
519 ESADMSIGVTVIKNNMI 535 97 100 100 99
----------------T # - - 1
525 IGVTVIKNNMINNDLGP 541 97 100 100 99
537 NDLGPATAQMALQLFIK 553 98 100 100 99
S---------------- 0.11 - - 1
548 LQLFIKDYRYTYRCHRG 564 98 100 100 100
554 DYRYTYRCHRGDTQIQT 570 98 100 100 99
------------A---- 0.04 - - 1
PB2 126 KHGTFGPVHFRNQVKIR 142 96 96 - 98
-Y--------------- # - - 1
---S------------- # - - 1
-Q--------------- 0.14 3 100 -
132 PVHFRNQVKIRRRVDIN 148 88 100 100 -
---------------T- 4 - - 100
500 RFLRVRDQRGNVLLSPE 516 92 100 100 100
630 RMQFSSLTVNVRGSGMR 646 97 100 100 -
---------------L- 1 - - 100
M1 175 HENRMVLASTTAKAMEQ 191 98 100 100 100
181 LASTTAKAMEQMAGSSE 197 95 100 100 100
1Highly conserved aa of 1977–2006 influenza A subtypes are boldface.
*3175 PB1, 3144 PB2, and 3781 M1 human H1N1, H3N2, H1N2, H5N1, and avian H5N1 and other avian subtypes sequences circulating between 1977 and 2006 were
extracted from NCBI GenBank and GenPept databases as of September 2006. Sequences representing less than 1% were not included unless they were also represented
in the 2007–2009 strains.
All human PB1, PB2, and M1 H1N1 sequences from 2007 to 2009 were extracted from the Influenza Virus Resource on Jun 17, 2009.
+168 PB1, 171 PB2, and 280 M1 human H1N1 2009 sequences.
ˆ31 PB1, 31 PB2, and 39 M1 human H1N1 2008 sequences.
0314 PB1, 314 PB2, and 393 M1 human H1N1 2007 sequences.
#New sequence representation not found in the 1977–2006 influenza A subtypes sequences.
doi:10.1371/journal.pone.0008754.t004
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recorded avian and human influenza A viruses, including the
H1N1 isolates. Further, they are clustered and have distinct
advantages in the design of an epitope-based genetic vaccine,
including the retention of native sequences for the function of
transporters associated with antigen processing (TAPs) [42] and
for the flanking sequences that are reported to modulate epitope
processing and function in the selection of immunodominant
epitopes [43]. Each of these 17 sequences, except M1181–197 and
PB1537–553, was also characterized by high apparent functional
avidity at the lowest peptide concentration of 0.1 mg/ml in the
IFN-c ELISpot assay. Several studies showed that high avidity
CD8+ T cells were more effective in limiting viral replication in
vitro [44–46]. Further, the 17 T cell epitopes had no identity of 8 or
more continuous aa to human peptides that might trigger onset of
human autoimmune diseases by priming autoreactive T cells. It is
also noteworthy that several of the epitopes are located in
described functional domains: PB1518–575 in the interacting
domain of PB1 with PB2 (PB1506–659) [47]; and the overlapping
PB2126–142 and PB2132–148 in the PB1- and NP-binding domain of
PB21–269 [48]. T cell epitopes within funtional domains would
remain conserved over time as viral mutations useful towards
immune escape may disrupt the function of the domains and affect
viral fitness unless compensated functionally by multiple co-
mutations [49,50]. Thus, a T cell-based vaccine including these 17
highly conserved T cell epitopes, as described in this study, may
possibly greatly reduce, if not eliminate, the incidence of variant
amino acids of the corresponding T cell epitopes of any future
influenza A pathogen.
Table 5. Representation of 9 H1N1 T cell epitope sequences with single amino acid substitutions from the most frequent
sequences ($ 80% conservation) among all influenza A 1977–2006 strains and H1N1 strains 2007–2009.
Protein
A/New York/348/2003 H1N1
ELISpot positive peptide1
1977--2006
Influenza A*
2007 human
H1N10
2008 human
H1N1 “
2009 human
H1N1+
PB1 ---------------K- 86 - - 99
37 GYTMDTVNRTHQYSERG 53 13 99 84 -
-----------R---K- # - - 1
-----------H----- # - 16 -
----------I------ 89 1 - -
507 MELPSFGVSGVNESADM 523 10 99 100 100
----------------L 86 - - 99
560 RCHRGDTQIQTRRSFEI 576 11 100 100 -
------A---------L 0.04 - - 1
----S------------ 84 - - 100
650 GPAKNMEYDAVATTHSW 666 12 99 97 -
-----I----------- 0.68 - 3 -
----T------------ 0.42 1 - -
-----------I----- 87 - - 96
656 EYDAVATTHSWVPKRNR 672 11 100 100 -
-----------T----- 0.76 - - 4
-----------K----- 85 - - 100
680 RGILEDEQMYQRCCNLF 696 10 98 87 -
--V-------------- 0.23 1 10 -
----------L------ # - 3 -
PB2 -------------Q--- 89 - - 100
434 LLRHFQKDAKVLFLNWG 450 7 97 100 -
---------R------- 0.03 1 - -
----------I------ 0.03 1 - -
-----------V----- 90 - - 99
536 MWEINGPESVLINTYQW 552 8 100 100 1
-----V----------- 84 - - 99
542 PESVLINTYQWIIRNWE 558 8 99 100 1
1Highly conserved aa of 1977–2006 influenza A subtypes are boldface.
*3175 PB1 and 3144 PB2 human H1N1, H3N2, H1N2, H5N1, and avian H5N1 and other avian subtypes sequences circulating between 1977 and 2006 were extracted
from NCBI GenBank and GenPept databases as of September 2006. Sequences representing less than 1% were not included unless they were also represented in the
2007–2009 strains.
All human PB1 and PB2 H1N1 sequences from 2007 to 2009 were extracted from the Influenza Virus Resource on Jun 17, 2009.
+168 PB1 and 171 PB2 human H1N1 2009 sequences.
ˆ31 PB1 and 31 PB2 human H1N1 2008 sequences.
0314 PB1 and 314 PB2 human H1N1 2007 sequences.
#New sequence representation not found in the 1977–2006 influenza A subtypes sequences.
doi:10.1371/journal.pone.0008754.t005
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Supporting Information
Figure S1 Selected 196 peptides of Influenza A/New York/
348/2003 (H1N1) used for mapping T cell responses in 6 HLA
transgenic mouse strains (A2, A24, B7, DR2, DR3, and DR4).
Red bold amino acids are conserved residues. Numbers represent
residue positions. Overlapping residues were aligned.
Found at: doi:10.1371/journal.pone.0008754.s001 (0.05 MB
DOC)
Table S1 The first immunization peptide pool consisted of 13
M1 and 84 PB2 peptides of A/New York/348/2003 (H1N1)
containing the highly conserved aa.
Found at: doi:10.1371/journal.pone.0008754.s002 (0.08 MB
DOC)
Table S2 The second immunization peptide pool consisted of 28
NP, 23 PA, and 48 PB1 peptides of A/New York/348/2003
(H1N1) containing the highly conserved aa.
Found at: doi:10.1371/journal.pone.0008754.s003 (0.08 MB
DOC)
Table S3 Representation of 28 (9 NP, 4 PA, 9 PB2, 5 PB1, and 1
M1) T cell epitope peptides of A/New York/348/2003 (H1N1)
among human H1N1, H3N2, H1N2, H5N1, and other avian
subtypes circulating between 1977 to 2006.
Found at: doi:10.1371/journal.pone.0008754.s004 (0.16 MB
DOC)
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